{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:49:47Z","timestamp":1792698587911,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamaneurol.2018.4905","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T15:02:34Z","timestamp":1550502154000},"page":"536","source":"Crossref","is-referenced-by-count":351,"title":["Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis"],"prefix":"10.1001","volume":"76","author":[{"given":"Katharine","family":"Harding","sequence":"first","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"},{"name":"Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owain","family":"Williams","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Willis","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hrastelj","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rimmer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wardle","sequence":"additional","affiliation":[{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Pickersgill","sequence":"additional","affiliation":[{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Robertson","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Tallantyre","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom"},{"name":"Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi180112r1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jama.2012.7625","article-title":"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.","volume":"308","author":"Shirani","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"noi180112r2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.","volume":"14","author":"Palace","year":"2015","journal-title":"Lancet Neurol"},{"issue":"81","key":"noi180112r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20810","article-title":"Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.","volume":"20","author":"Tilling","year":"2016","journal-title":"Health Technol Assess"},{"issue":"4","key":"noi180112r4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era.","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"2","key":"noi180112r5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaneurol.2013.1017","article-title":"Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.","volume":"70","author":"Greenberg","year":"2013","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi180112r6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol"},{"issue":"12","key":"noi180112r7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/jnnp.2010.229724","article-title":"Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.","volume":"82","author":"Edan","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"noi180112r8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1212\/WNL.0b013e3181c1e44f","article-title":"Impact of multiple sclerosis relapses on progression diminishes with time.","volume":"73","author":"Tremlett","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"noi180112r9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract Neurol"},{"issue":"10","key":"noi180112r10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients.","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"noi180112r11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions.","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"noi180112r12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/jnnp.51.12.1520","article-title":"The prevalence of multiple sclerosis in south east Wales.","volume":"51","author":"Swingler","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"noi180112r13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/jnnp.52.9.1085","article-title":"The incidence and mortality of multiple sclerosis in south east Wales.","volume":"52","author":"Hennessy","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"noi180112r14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s004150050508","article-title":"Urinary, faecal and sexual dysfunction in patients with multiple sclerosis.","volume":"246","author":"Hennessey","year":"1999","journal-title":"J Neurol"},{"issue":"4","key":"noi180112r15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/jnnp.2008.144667","article-title":"Increasing prevalence and incidence of multiple sclerosis in South East Wales.","volume":"80","author":"Hirst","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"noi180112r16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"noi180112r17","doi-asserted-by":"publisher","first-page":"e59694","DOI":"10.1371\/journal.pone.0059694","article-title":"The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform.","volume":"8","author":"Jokubaitis","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"noi180112r18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs interferon beta-1a in early multiple sclerosis.","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"noi180112r19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.","volume":"22","author":"Willis","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"noi180112r20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00415-008-0743-8","article-title":"Contribution of relapses to disability in multiple sclerosis.","volume":"255","author":"Hirst","year":"2008","journal-title":"J Neurol"},{"key":"noi180112r21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments.","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"issue":"5","key":"noi180112r22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1352458512460605","article-title":"Scoring treatment response in patients with relapsing multiple sclerosis.","volume":"19","author":"Sormani","year":"2013","journal-title":"Mult Scler"},{"issue":"3","key":"noi180112r23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations.","volume":"40","author":"Freedman","year":"2013","journal-title":"Can J Neurol Sci"},{"issue":"12","key":"noi180112r24","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/1352458510379245","article-title":"A method for evaluating treatment switching criteria in multiple sclerosis.","volume":"16","author":"Healy","year":"2010","journal-title":"Mult Scler"},{"issue":"4","key":"noi180112r25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"noi180112r26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9856","key":"noi180112r27","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaneurology\/article-pdf\/76\/5\/536\/17579728\/jamaneurology_harding_2019_oi_180112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:02:32Z","timestamp":1557745352000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.4905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.4905","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}